Q3 2023
Released Feb 3, 2023, before the open
10-Q filed Feb 3, 2023, 34 days after period end · 0001764013-23-000022
Q3 2023 · 10-Q
Revenue—
Net Income-$63.23M-$63.23M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.49-$0.49 N/M vs Q3 2022N/M vs Q2 2023
Operating Cash Flowderived-$46,395,000N/M
Free Cash Flowderived-$46,493,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2018 |
|---|---|---|---|
| Net Income | -$63.23M | -$41.39M | -$8.85M |
| EPS Diluted | -$0.49 | -$0.36 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR